Mabwell to Showcase New Clinical Findings on Urothelial Carcinoma at ASCO 2026

Mabwell to Present Latest Findings at ASCO 2026

Mabwell, a biopharmaceutical company recognized for its innovation, is set to unveil novel clinical data regarding its Nectin-4-targeting antibody-drug conjugate (ADC) known as 9MW2821. This data highlights the ADC's effectiveness when combined with toripalimab for patients suffering from urothelial carcinoma during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Scheduled to run from May 29 to June 2, 2026, in Chicago, the ASCO Annual Meeting is a premier platform for researchers and clinicians in the field of oncology to share groundbreaking data. Mabwell's participation in this event underscores its commitment to advancing cancer treatment through innovative therapeutic strategies.

Highlighted Presentations

The company will feature two distinct presentations highlighting its pivotal clinical studies:
1. Oral Presentation:
- Title: Bulumtatug fuvedotin (BFv; 9MW2821) alongside toripalimab in patients diagnosed with locally advanced or metastatic urothelial carcinoma (la/mUC)
- Abstract Number: 4518
- Presenter: Prof. Sheng Xinan, Chief Physician and doctoral supervisor at the Department of Urologic Oncology, Beijing Cancer Hospital
- Session Date and Time: June 1, 2026, from 8:00 AM to 9:30 AM CDT

2. Poster Presentation:
- Title: Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab among perioperative patients with muscle-invasive bladder cancer (MIBC)
- Abstract Number: 4609
- Principal Investigator: Prof. Liu Zhuowei, Chief Physician at the Department of Urology, Sun Yat-sen University Cancer Center
- Session Date and Time: May 31, 2026, from 9:00 AM to 12:00 PM CDT

The findings presented at ASCO are anticipated to shed light on the efficacy of 9MW2821 in conjunction with toripalimab, especially in addressing unmet medical needs for patients with challenging forms of cancer.

Mabwell’s Mission and Vision

Founded with the central mission of delivering innovative treatments that can meet pressing medical needs, Mabwell strives for excellence across the entire pharmaceutical value chain. This commitment is embodied in its operational motto, “Explore Life, Benefit Health,” and reinforces its vision of transforming innovative ideas into tangible healthcare solutions.

With a focus on oncology and diseases associated with aging, Mabwell aims to enhance treatment accessibility and effectiveness. The company's innovative spirit is reflected in its ongoing dedication to research and development efforts that drive clinical advancement.

As Mabwell gears up for its presentations at ASCO 2026, the engaged oncology community anticipates valuable insights that may revolutionize treatment approaches available to those diagnosed with urothelial carcinoma.

For detailed information on Mabwell and its advancements in biopharmaceuticals, please visit Mabwell's official website.